# Simplify Genomics | Investor Update – 1H 2025 | Simplify Genomics

- Canonical URL: https://wefunder.com/feed/184206
- Entity ID: wefunder:feed_item:184206
- Published at: 2025-07-29 19:54:51 UTC
- Updated at: 2025-08-01 22:32:59 UTC

## Author
Travis Lacey

## Subject
Simplify Genomics

## Content
Dear Investors,Thank you for your continued support of Simplify Genomics. We are energized by the progress made in the first half of 2025 and are optimistic about the growth trajectory ahead. In this update, we highlight key developments across the business, the broader market, and outline our priorities for the remainder of the year.Our MissionAt Simplify Genomics, we are revolutionizing clinical decision-making through genomic reporting and real-time genome exploration. Our platform is comprised of three integrated, complementary products:1. Simplify Genome: A CLIA-licensed and CAP-accredited, end-to-end clinical reporting solution built for Whole Genome Sequencing at scale.2. Simplify Search: An AI-powered engine offering rapid access to raw ‘omics data, clinical phenotypes, and the current state of genomics knowledge at the speed of thought.3. Simplify Data: A unified resource combining public and proprietary ‘omic and clinical datasets, powering both our reporting and research analytics platforms.Market LandscapeThe past three years have been challenging across the life sciences sector, but recent trends are increasingly favorable. In the last quarter alone, we’ve observed renewed activity in genomics—reflected in strategic acquisitions and financings—which affirms strong market tailwinds for our solutions.Two major shifts are now evident:·      A move toward Whole Exome and Whole Genome sequencing, away from more limited panel testing and array testing. This is driven by the reduction in costs of these technologies.·      An increase in the need for tools that convert raw genomic data into clinically actionable insights.Simplify Genomics is uniquely positioned to capitalize on both.Another recent and notable signal came from Florida’s legislative action via the Sunshine Genetics Act, which prioritizes Whole Genome sequencing of newborns to expedite the diagnosis of rare diseases. We’ve proactively engaged with Florida officials, including Rep. Adam Anderson and Dr. Pradeep Bhide, to learn more and gain a better understanding of the details. With over a decade of investment in clinical Whole Genome reporting, our platform is well-positioned to support such initiatives with the scale, accuracy, and speed required. Business Highlights – 1H 2025Commercial Progress·      Client Growth: We onboarded four new concierge clients, incorporating our clinical genome report into their practices. We received ~850 report orders in the first half, up 15% over the previous six months. Historically, our growth has been driven by word of mouth, and we’ve now initiated commercial outreach to further accelerate growth over the next 12 months.·      Search Platform Beta: Granted beta access to prospective clients for our Simplify Search platform to gather feedback and refine the product.·      New Revenue Stream: Signed a commercial contract enabling a client to conduct research on their genomic data via our Smart Genome Platform.·      Upcoming Partnership Launch: Partnering with a major imaging center to integrate our whole genome report with their full-body MRI service. Initially slated for Q3, the launch was rescheduled for Q4 2025 as we validate the use of saliva (as opposed to blood) to simplify the collection process and enhance adoption.Product & Operational Milestones·      Team Expansion: Hired a Principal DevOps and InfoSec Engineer, delivering immediate impact. Culture and work ethic are of utmost importance to us, and we had worked with him before in the past and knew he would contribute immediately. Although we are spend and cost-conscious, we will continue to make selective hires of additional key personnel as we scale. ·      Sample Flexibility: We are currently validating saliva as an input specimen type (in addition to whole blood). This will be a key enabler for a broader commercial deployment, particularly for customers without on-site phlebotomy services. We anticipate completion of this in Q4 25.·      Cross-Lab Compatibility: We are progressing with validation of genomic data from other accredited labs, primarily to support an upcoming partner, TMA Precision Health. TMA’s mission aims to drastically reduce rare disease diagnostic timelines—from seven years to mere weeks—using our genomic insights to improve patient care planning. With tens of millions of people living with some form of rare disease, the opportunities are significant for Simplify to grow with TMA. ·      Expanded Report Scope: We are enhancing our Simplify Genome report to cover over 3,000 annotated genes. This significantly extends its clinical utility, positioning it as one of the most comprehensive reports in the market. We project completion by the end of Q4 25.·      Cost Optimization: We initiated a project to reduce Simplify Genome’s cost of goods by 20%, enabling more competitive pricing while continuing to target gross margins of 60% or higher. Our goal is to reduce the pricing of our product while maintaining gross margins.·      Regulatory Readiness: We are preparing for our biannual CAP inspection scheduled for later this year.·      Search Platform Scaling: Simplify Search now indexes over 400 million distinct variants, with a target of 1 billion or more variants in the next 12 months — all while maintaining instant query response times.Looking AheadThe demand for scalable, clinically relevant Whole Genome analytics is accelerating. Simplify Genomics is exceptionally well-positioned to lead this transformation through its integrated platform, proven operational excellence, and commitment to cost-effective innovation. As always, we are grateful to be backed by supportive investors who see the opportunity and share our vision.Please don’t hesitate to reach out with questions, feedback, or opportunities for collaboration.Warm regards,The Simplify Genomics Teamwww.simplifygenomics.com | support@simplifygenomics.com